<i>In vitro</i> evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy-Reference-Cited by-同舟云学术

In vitro evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy

Published:2022 Issue:11 Volume:10 Page:2865-2876
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Pei Mengyue¹,Li Huiyang¹,Zhu Yingwei²³,Lu Jian³,Zhang Chuangnian¹⁴^ORCID

Affiliation:

1. Tianjin Key Laboratory of Biomaterial Research, Biomedical Barriers Research Center, Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China

2. Department of Gastroenterology, The Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, Wuxi city, 214002, China

3. Department of Gastroenterology, Wuxi No. 2 People's Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi city, 214002, China

4. State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, 300353, China

Abstract

Antigen and adjuvant co-delivery nanovaccines were prepared to induce antigen-specific antitumor immune responses against liver cancer.

Funder

National Natural Science Foundation of China

State Key Laboratory of Medicinal Chemical Biology

Wuxi Health and Family Planning Commission

Peking Union Medical College

Chinese Academy of Medical Sciences Initiative for Innovative Medicine

Wuxi Municipal Bureau on Science and Technology

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2022/BM/D1BM02021H

Reference43 articles.

1. Cancer statistics, 2020

2. Combinatorial immunotherapy strategies for hepatocellular carcinoma

3. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy

4. Insights into the success and failure of systemic therapy for hepatocellular carcinoma

5. Immunological landscape and immunotherapy of hepatocellular carcinoma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered Bio‐Based Hydrogels for Cancer Immunotherapy;Advanced Materials;2024-02-22

2. Recent advances in engineering prodrug-based nanomedicines for cancer therapy;Materials Advances;2024

3. Smart Polymeric Nanoparticles in Cancer Immunotherapy;Pharmaceutics;2023-02-26

4. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy;Frontiers in Pharmacology;2023-02-16

5. Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC;Scientific Reports;2023-02-11